4 result(s) displayed (1 - 4 of 4):

Glaxo chief JV'ing his way to profits (from Corporate Dealmaker)

After watching his rivals consolidate and generic competition squeeze the company's earnings, GlaxoSmithKline plc (NYSE:GSK) chief executive Andrew Witty started allying to expand in emerging markets and shift money from pharmaceuticals into vaccines and consumer businesses.The latest deal is a revenue-sharing agreement with India's Dr. Reddy's Laboratories Ltd. (NYSE:RDY),...

Posted on June 16, 2009 12:52 PM

Glaxo making good on strategic shift (from Corporate Dealmaker)

As its first-quarter results were hammered by generic competition, GlaxoSmithKline plc (NYSE:GSK) chief executive Andrew Witty's game plan is to stay away from megamergers, expand in emerging markets and shift money from pharmaceuticals into vaccines and consumer businesses as more blockbuster drugs face generic competition. One such drug is its...

Posted on May 6, 2009 9:03 AM

Stiefel may keep acquiring as part of GSK (from Corporate Dealmaker)

GlaxoSmithKline plc (NYSE:GSK) is acquiring the world's largest independent dermatology company, Stiefel Laboratories Inc., for up to $3.6 billion. So far most reports have focused on Glaxo CEO Andrew Witty's strategy, which includes staying away from megamergers, expanding in emerging markets and shifting money from pharmaceuticals into vaccines and...

Posted on April 20, 2009 5:39 PM

Reports: Glaxo may acquire stake in Aspen Pharmacare (from Corporate Dealmaker)

News of pharma consolidation continued Thursday with various reports, including from The Wall Street Journal and Reuters, saying GlaxoSmithKline plc (NYSE:GSK) is in talks to acquire a minority stake in South African generic drugmaker Aspen Pharmacare Holdings Ltd. The Journal says Glaxo will likely buy 25% of Aspen, which has...

Posted on March 26, 2009 8:21 AM